USA, Antigen Discovery Gets Grant for Developing Chlamydia Vaccine

Antigen Discovery, Inc., a biotech company in high throughput antigen and biomarker discovery, was awarded a $1.8 million Phase II Small business technology transfer research (STTR) grant.
The grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the American Recovery and Reinvestment Act (ARRA) of 2009.
The funds will be used to further test and validate novel candidate antigens discovered during the Irvine, CA.-based company’s successful STTR Phase I program. Antigen Discovery will develop the novel antigens as core protective components in a vaccine against Chlamydia, collaborating with investigators in the Department of Pathology & Laboratory Medicine of School of Medicine at the University of California, Irvine (UCI).

Join the discussion